We are proud to announce True’s participation in the €4m Seed round of Cambiotics, led by Collaborative Fund with participation from True and EIFO.
We first came across Cambiotics at the TechBBQ conference in Copenhagen in late 2024. As we walked around the start-up stands between meetings, a little-known acronym on the roller banner of one company stood out: “PFAS” (per- and polyfluoroalkyl substances).
Some of the health and fitness content creators we track had started mentioning PFAS – sometimes referred to as ‘forever chemicals’ – as an underappreciated human health crisis. The story is not a hopeful one. PFAS chemicals – synthetic compounds used since the 1940s to make products resistant to water, oil, stains, and heat – are everywhere in the environment, and most scarily, rife throughout the human body. They’re associated with a host of human health issues, from cancer and endocrine disruption to infertility and developmental issues in children. And perhaps worst of all, there’s not much you can do about them: PFAS come into our bodies through ingestion and the worst type – long-chain PFAS like PFOA and PFOS – accumulate over time, with no clear mechanism to get rid of them. They are, as the ‘forever chemical’ name implies, extremely difficult to break down.
Cambiotics represented something unique: a potential way out. A practical solution for consumers to take back control and detoxify their bodies from this ubiquitous pollutant.
We connected with Peter and the team to learn more. They weren’t fundraising at the time, but we used the opportunity to dig into the problem, market opportunity and competitive landscape. The more we learnt, the more our conviction grew that PFAS would become a megatrend amongst a consumer base increasingly focused on health and wellness. It was clear there are no direct, science-backed solutions out there. It needed a breakthrough.
Cambiotics and its consumer-facing brand, 46&, is exactly that kind of breakthrough: a science-backed supplement delivering proprietary probiotics and postbiotics to capture PFAS chemicals in the gut and help them pass through the human body. Led by a mission-driven serial entrepreneur in Peter Holme Jensen, alongside University of Cambridge scientists Kiran Patil and Anna Lindell, we believe Cambiotics is the missing solution to a truly enormous problem.
After regular check-ins and updates over the last year or so, the stars finally aligned for us to have the opportunity to invest. We could not be more excited to support Peter and the team on their mission to help millions of consumers address one of the biggest emergent threats to human health and flourishing. We are also delighted that this is our first investment in Denmark and we look forward to partnering with other ambitious entrepreneurs across Denmark and the wider Nordics in future.
True’s focus will be on bringing our consumer sector expertise to help launch and scale 46& in major markets globally. You can sign up to the 46& waitlist here.
To learn more about True’s VC fund backing mission-driven entrepreneurs at the forefront of consumer behavioural change, check out our page on the True website here.
